Introduction
Cardiovascular diseases are the main complication experienced by elderly individuals with diabetes (1) . Despite randomized trials showing the benefits of individual (2) (3) (4) or combined (5) pharmacological treatments of cardiovascular risk factors in diabetes, observational studies have showed suboptimal use of medications (6) (7) (8) . However, little is known about the use of cardioprotective medications among elderly individuals who were not already taking it before diabetes treatment was undertaken. We therefore studied a population of elderly with type 2 diabetes in the province of Quebec, Canada, who had not been treated with any antihypertensive, lipid-lowering or antiplatelet drugs in the year before oral antidiabetic drug initiation. We assessed whether they used a Comprehensive Cardioprotective Regimen (CCR) of those three medications in the year following oral antidiabetic initiation. We also identified the determinants of a CCR use.
Research design and methods
We carried out a population-based inception cohort study using the Quebec Diabetes Surveillance System (QDSS). The QDSS results from linking public health administrative databases managed by the Quebec Health Insurance Board. It includes information on patient demographics, physician and hospital services and data from the public drug plan for individuals who had been diagnosed with diabetes.
We selected individuals aged 66 years and over who had initiated an oral antidiabetic treatment between 1 January 1998 and 31 December 2002. The date of the first claim was the index date. We excluded those individuals who had received any insulin, oral antidiabetic, antiplatelet, antihypertensive or lipid lowering drugs during the 365 days prior to the index date. We also excluded those who had not been beneficiaries of the drug plan for the entire 365-day period prior to the index date, and individuals who had not at least a one year follow-up.
A person was deemed to have a CCR if there was at least one claim for each of 1) an antihypertensive, 2) a lipid lowering and 3) an antiplatelet drug in the year following the index date. Each of the three drugs could be used at different times during follow-up.
Potential determinants of CCR use included: sex, age, and residential area of the individuals, year of oral antidiabetic agent initiation and whether the oral antidiabetic therapy was initiated in the 14 days post-hospitalization. Other potential determinants measured in the year prior to the index date were included: 1) number of outpatient medical visits, 2) hospitalization, and 3) suffering from cardiovascular disease.
The proportion of individuals using a CCR was calculated. Determinants of CCR use were identified using multivariate logistic regression. Odds ratios and their 99% confidence intervals were calculated. Analyses were carried out using SAS Version 9.1. In the multivariate analysis, three out of eight potential determinants of CCR use remained statistically significant at the alpha level of 0.01 (table 1 ). An older age at oral antidiabetic therapy initiation was inversely associated with CCR use, whereas suffering from cardiovascular disease was positively associated with the use of a CCR. The odds of being exposed to a CCR also increased over the time period 
Conclusion
Among elderly individuals not exposed to cardiovascular drugs in the year before the initiation of oral antidiabetic therapy, the proportion of CCR users is low (7.6%). If diabetes is to be considered a cardiovascular equivalent (9), these results suggest that the management of cardiovascular risk for those patients is less than appropriate.
Other studies have demonstrated gaps in the use of cardiovascular risk-modifying drugs among elderly individuals with diabetes (10-11). Of 105,715 elderly individuals in Ontario, Canada, around two third used antihypertensive agents and about one-quarter received a lipid lowering drug in a period of six months following the first year of diabetes diagnosis (11) .
A low proportion of the combined use of antiplatelet drugs, statins and ACE inhibitors was also found in a cohort of individuals with various-length-duration diabetes, in Saskatchewan, Canada (12) . In that study, of 12,106 patients aged 30 to 105 years, 596 (5%) used the combined treatment (12) .
Some of the factors associated with CCR use in our study have been observed by others. Younger type 2 diabetes patients (13) and those suffering from cardiovascular disease (14) were found to be more likely to obtain aggressive cardiovascular treatments. Improvement in use of cardiovascular drugs through recent years has been reported (8, 15) . On the other hand, it has been reported that women with diabetes were less likely than men to receive acetylsalicylic acid (14, 16) or lipid-lowering drugs (17), or to have blood pressure and cholesterol levels below current targets (18) . In our population of newly treated individuals, sex did not appear to influence the use of a CCR.
The unavailability of clinical data in the administrative data used represents a limitation of the study, making difficult the evaluation of individual appropriateness of CCR use. However, according to clinical guidelines, the majority of individuals would qualify to CCR use. Most elderly require pharmaceutical agents in order to reach aggressive blood pressure (130/80 mmHg) and LDL-cholesterol targets (2.6 mmol/L) (19, 20) . The vast majority of elderly with diabetes should also be using ACE inhibitors or angiotensin receptor antagonists for vascular protection (21) . Moreover, all individuals included in our study should have received an antiplatelet drug unless contra-indicated (19, 20 † Metropolitan: urban core of at least 100,000 people and its adjacent municipalities; Agglomeration: urban core of at least 10,000 people and its adjacent municipalities; Rural: municipalities not included in the two former categories. ∫ A person was deemed to have a cardiovascular disease if there were any outpatient or hospital ICD-9 code for ischemic cardiac disease, heart failure or cerebrovascular disease, or a procedural code of revascularization, coronary bypass or peripheral limb revascularization recorded. A person with a prescription claim for a nitrate was also considered as having cardiovascular disease.
